Track Wixela Inhub price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Wixela Inhub Costs $126.00 Per Claim
Wixela Inhub (Fluticasone/Salmeterol (generic)) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $234.0M on this drug, covering 224,000 beneficiaries across 1,860,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Fluticasone/Salmeterol (generic) or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Wixela Inhub increased by +18.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Wixela Inhub (Fluticasone/Salmeterol (generic)) costs an average of $126.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,045.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Wixela Inhub averages $126.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Wixela Inhub reflects in our Medicare Part D average of $126.00 per claim. Switching to generic Fluticasone/Salmeterol (generic) typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Wixela Inhub, but coverage varies by formulary tier. Insurers typically prefer generic Fluticasone/Salmeterol (generic) (Tier 1, lowest copay) over brand-name Wixela Inhub (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Fluticasone/Salmeterol (generic) is the single biggest cost reducer if your prescriber is open to it.
Brand-name Wixela Inhub costs more than generic Fluticasone/Salmeterol (generic) primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Wixela Inhub (Fluticasone/Salmeterol (generic)) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Fluticasone/Salmeterol (generic).
Medicare Part D spent $234.0M on Wixela Inhub, covering 224,000 beneficiaries across 1,860,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Fluticasone/Salmeterol (generic), which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Wixela Inhub's Medicare Pricing
At $126.00 per claim, Wixela Inhub is a mid-priced medication — more than a bargain generic but well short of a specialty product. Drugs in this range are often brands with partial competition, recently-genericized molecules still carrying brand pricing, or moderately complex formulations. The cost is real but rarely catastrophic for asthma/copd, and a same-class or generic substitute frequently closes most of the gap.
Medicare spent $234.0M on Wixela Inhub across 1,860,000 claims and 224,000 beneficiaries — a mid-size line item. Drugs in this tier rarely make headlines but collectively make up the bulk of Part D spending. The interplay between the $126.00 average claim cost and the claim volume is what decides whether this drug's total trends up or down year to year.
Because a generic version of Fluticasone/Salmeterol (generic) is on the market, the realistic savings path for Wixela Inhub is straightforward: the generic is therapeutically equivalent and typically costs a fraction of the brand. The friction is usually prescribing habit rather than availability — patients can ask the prescriber to write for the generic, and most plans already steer to it with a lower copay tier. That single switch usually beats coupons, assistance programs, and pharmacy shopping combined.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $126.00 as a consistent Medicare-program benchmark for Wixela Inhub, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.